谷歌浏览器插件
订阅小程序
在清言上使用

Comparison of Predicted Benefit Using RS Clin Versus Observed Benefit in a US Registry of Stage I ER-positive HER2-negative High Oncotype DX RS Breast Cancer.

Christopher David Walden, Samuel Mosiman,Andrew J. Borgert,Benjamin Marshall Parsons

JOURNAL OF CLINICAL ONCOLOGY(2022)

引用 0|浏览18
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要